JP2023537222A5 - - Google Patents
Info
- Publication number
- JP2023537222A5 JP2023537222A5 JP2023503448A JP2023503448A JP2023537222A5 JP 2023537222 A5 JP2023537222 A5 JP 2023537222A5 JP 2023503448 A JP2023503448 A JP 2023503448A JP 2023503448 A JP2023503448 A JP 2023503448A JP 2023537222 A5 JP2023537222 A5 JP 2023537222A5
- Authority
- JP
- Japan
- Prior art keywords
- superantigen
- cancer
- superantigen conjugate
- conjugate according
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063053859P | 2020-07-20 | 2020-07-20 | |
| US63/053,859 | 2020-07-20 | ||
| PCT/IL2021/050882 WO2022018726A1 (en) | 2020-07-20 | 2021-07-20 | Superantigen conjugate for use in methods and compositions for treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023537222A JP2023537222A (ja) | 2023-08-31 |
| JP2023537222A5 true JP2023537222A5 (cg-RX-API-DMAC7.html) | 2024-07-24 |
Family
ID=79728646
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023503448A Pending JP2023537222A (ja) | 2020-07-20 | 2021-07-20 | 癌を治療するための方法および組成物における使用のためのスーパー抗原コンジュゲート |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230285588A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4181965A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023537222A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230085904A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116490521A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021313881A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3173909A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL299950A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022018726A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111201030B (zh) | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | 通过阻断tim-3和其配体的相互作用治疗癌症 |
| KR20210124308A (ko) | 2019-01-30 | 2021-10-14 | 트루바인딩 아이엔씨. | 항-gal3 항체 및 이의 용도 |
| MX2022014786A (es) | 2020-05-26 | 2023-01-16 | Truebinding Inc | Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3. |
| CN120847420B (zh) * | 2025-09-23 | 2025-12-02 | 天津医科大学总医院 | T细胞亚群在制备评估b细胞耗竭疗法试剂盒中的应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003061694A1 (en) * | 2001-05-10 | 2003-07-31 | Seattle Genetics, Inc. | Immunosuppression of the humoral immune response by anti-cd20 antibodies |
| SE0102327D0 (sv) * | 2001-06-28 | 2001-06-28 | Active Biotech Ab | A novel engineered superantigen for human therapy |
| EP3411409B1 (en) * | 2016-01-10 | 2025-10-08 | Neotx Therapeutics Ltd. | Anti pd-1/anti-pd-l1 antibodies for enhancing the potency of superantigen mediated cancer immunotherapy |
-
2021
- 2021-07-20 KR KR1020237005638A patent/KR20230085904A/ko not_active Withdrawn
- 2021-07-20 JP JP2023503448A patent/JP2023537222A/ja active Pending
- 2021-07-20 WO PCT/IL2021/050882 patent/WO2022018726A1/en not_active Ceased
- 2021-07-20 US US18/006,243 patent/US20230285588A1/en active Pending
- 2021-07-20 CN CN202180064210.5A patent/CN116490521A/zh active Pending
- 2021-07-20 EP EP21846878.3A patent/EP4181965A4/en active Pending
- 2021-07-20 CA CA3173909A patent/CA3173909A1/en active Pending
- 2021-07-20 IL IL299950A patent/IL299950A/en unknown
- 2021-07-20 AU AU2021313881A patent/AU2021313881A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI786044B (zh) | 藉由投予pd-1抑制劑治療皮膚癌之方法 | |
| KR102333658B1 (ko) | 비-소세포 폐암을 치료하기 위한 항-b7-h1 및 항-ctla-4 항체 | |
| WO2019140150A1 (en) | Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer | |
| WO2022174775A1 (en) | Use of antibody-drug conjugate targeting her2 in treatment of specific breast cancer | |
| JP2023011902A (ja) | Pd-1阻害剤を投与することにより子宮頸がんを処置する方法 | |
| JP2023548051A (ja) | 肺がんのためのlag-3アンタゴニスト療法 | |
| JP2024519907A (ja) | 尿路上皮癌の治療における、免疫チェックポイント阻害剤と併用での抗体薬物複合体の使用 | |
| Huet et al. | Targeted nanofitin-drug conjugates achieve efficient tumor delivery and therapeutic effect in an EGFRpos mouse xenograft model | |
| EP4676541A1 (en) | Antitumor combinations containing anti-ceacam5 antibody-drug conjugates, anti-vegfr-2 antibodies and anti-pd1/pd-l1 antibodies | |
| WO2025078686A1 (en) | Combination therapy involving antibody-drug conjugates against claudin18.2 and pd1/pd-l axis inhibitors for treatment of cancer | |
| JP2025542297A (ja) | 肺癌の組み合わせ療法 | |
| AU2024286132A1 (en) | Antitumor combinations containing anti-ceacam5 antibody-drug conjugates, anti-pd1/pd-l1 antibodies and anti-ctla4 antibodies | |
| US20230061858A1 (en) | Treatment with site specific her2 antibody-drug conjugates | |
| RU2833461C1 (ru) | Способы лечения рака шейки матки путем введения инибитора pd-1 | |
| US20260132195A1 (en) | Anti-il-2 antibody combinations and methods of use thereof | |
| RU2861651C2 (ru) | Введение ингибиторов pd-1 для лечения рака кожи | |
| Toldrà et al. | American Association for Cancer Research (AACR)-113th Annual Meeting. New Orleans/Virtual-April 8-13, 2022 | |
| WO2026039321A1 (en) | Methods for treating prostate cancer | |
| Gennigens et al. | Emerging therapies in gynaecological cancers (part 1): Locally advanced and metastatic cervical cancer | |
| Teicher | Antibody drug and radionuclide conjugates for GI cancers | |
| WO2025256641A1 (zh) | 抗pd-l1抗体和抗ctla-4抗体联合治疗肿瘤 | |
| EP4297782A1 (en) | Methods of treating lung cancer by administering a pd-1 inhibitor | |
| WO2026046410A1 (zh) | 一种抗体药物偶联物与免疫检查点抑制剂的组合 | |
| Lézard | Datopotamab Deruxtecan Continues to Show Promising Durable Response and Disease Control in Patients with Metastatic Triple Negative Breast Cancer |